Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Abstract: An object is to provide a PRAM-binding molecule. This object is achieved by a PRAM-binding molecule comprising a heavy-chain variable region containing a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, and a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, and/or a light-chain variable region containing a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 9, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 10, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 11.

Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Abstract: CAR-T cells for cancer therapy are provided with an antibody that recognizes the MAGE-A4-derived-peptide/HLA-A2 complex. The antibody includes the VH amino acid sequence of SEQ ID NO: 36 and the VL amino acid sequence of SEQ ID NO: 38. The antibody preferably is provided with the amino acid sequence of SEQ ID NO: 32. Such CAR-T cells can be used in CAR infusion therapy in which a cancer-specific intracellular antigen is used.

Abstract: Provided is a cancer treatment or prevention technique that molecularly targets GD2. A GD2-binding molecule includes a heavy-chain variable region containing a heavy-chain CDR1 containing the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 containing the amino acid sequence represented by SEQ ID NO: 2, and a heavy-chain CDR3 containing the amino acid sequence represented by SEQ ID NO: 3, and/or a light-chain variable region containing a light-chain CDR1 containing the amino acid sequence represented by SEQ ID NO: 9, a light-chain CDR2 containing the amino acid sequence represented by SEQ ID NO: 10, and a light-chain CDR3 containing the amino acid sequence represented by SEQ ID NO: 11.

Abstract: A novel antigen receptor is provided. An antigen receptor contains a GITRL domain at a position closer to the C-terminus via a self-cleaving peptide domain.

Abstract: CAR-T cells for cancer therapy are provided with an antibody that recognizes the MAGE-A4-derived-peptide/HLA-A2 complex. The antibody includes the VH amino acid sequence of SEQ ID NO: 36 and the VL amino acid sequence of SEQ ID NO: 38. The antibody preferably is provided with the amino acid sequence of SEQ ID NO: 32. Such CAR-T cells can be used in CAR infusion therapy in which a cancer-specific intracellular antigen is used.

Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Abstract: An antibody library is prepared by selecting a light chain variable region capable of binding to the variable region of heavy chain to reproduce an active conformation and using the same. Because of being capable of maintaining the diversity of the heavy chain variable region at a high ratio in vitro, the antibody library of the present invention is expected as enabling the acquisition of antibodies with various binding activities.

Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Abstract: It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer.

Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Abstract: The present invention provides camel antibody libraries that maintain in vivo diversity of camelid antibody variable region genes. The in vivo diversity of antibody variable region genes can be accomplished by, for example, mixing genes derived from a plurality of animals or modifying gene amplification conditions. Conventional methods yield only VHHs with limited repertoire diversity. However, the present invention provides libraries comprising genes encoding functional VHHs with sufficient repertoire size. According to the present invention, libraries that enable to freely obtain VHHs against arbitrary antigens are provided. VHHs have excellent solubility and stability, and show a reactivity that usually cannot be expected from tetrameric IgGs.

Abstract: The present invention provides camel antibody libraries that maintain in vivo diversity of camelid antibody variable region genes. The in vivo diversity of antibody variable region genes can be accomplished by, for example, mixing genes derived from a plurality of animals or modifying gene amplification conditions. Conventional methods yield only VHHs with limited repertoire diversity. However, the present invention provides libraries comprising genes encoding functional VHHs with sufficient repertoire size. According to the present invention, libraries that enable to freely obtain VHHs against arbitrary antigens are provided. VHHs have excellent solubility and stability, and show a reactivity that usually cannot be expected from tetrameric IgGs.

Abstract: A binding molecule that binds to a binding target substance is selected by introducing an affinity linker into the target binding substance and capturing the substance with a binding partner that binds to the affinity linker. For example, an antibody that binds to an influenza virus antigen can be easily concentrated by labeling a sugar chain present in the antigen with an affinity linker, such as biotin, and then recovering the antigen by binding them to streptavidin. The method for selecting binding molecules of the present invention is also useful in the screening of neutralizing substances.

Abstract: Sintered silicon nitride containing silicon nitride substantially as a primary component and containing substantially no Al2O3. The sintered silicon nitride further contains at least one element selected from among a Group 4 element of the periodic table, a rare earth element and Mg. The amount of the selected element as converted to its oxide is at least 0.5 mol % and less than 2.6 mol % based on the entirety of the sintered silicon nitride. Also disclosed is a cutting tip, a wear-resistant member, a cutting tool and a method for producing the sintered silicon nitride.

Abstract: A lubricant composition for a refrigerating machine employing a HFC type refrigerant containing at least one selected from the group consisting of HFC-32, HFC-125 and HFC-134a, which comprises a base oil of an ester formed from a dihydric or higher polyol as an alcohol and a monobasic aliphatic acid, alone or as a mixture thereof; and additives of, based on the total amount, 1) not less than 0.01 vol % and less than 1.0 vol % of a phosphate, 2) from 0.01 to 1.0 vol % of at least one of an alkylphosphorothionate and an arylphosphorothionate and 3) from 0.01 to 1.0 vol % of an epoxy compound.

Abstract: A process for producing a hermetic electric compressor for a refrigerating or air-conditioning apparatus using a refrigerant having a hydrofluorocarbon base which comprises a motor unit, a compressing unit driven by the motor unit and a sealed housing enclosing the motor unit and the compressing unit and stores a refrigeration oil on the bottom of the sealed housing, wherein a solventless varnish comprising a thermosetting resin having at least two (meth)acryloyl groups in one molecule, a low-viscosity vinyl or 1-alkylvinyl monomer having an ether or ester linkage as a reactive diluent and an organic peroxide as a reaction initiator is used as an insulating varnish to insulate and fix the magnet wires of the stator of the motor unit, and the solventless varnish is cured by heating at a temperature of from 153 to 180.degree. C. for from 0.5 to 3.5 hours.

Abstract: In a refrigerant circulating apparatus, a liquid accumulating container for allowing oil droplets to flow out in suspended form is connected between a condenser and a pressure reducing device. Thus, refrigerating machine oil which flowed out from a compressor can be reliably returned to the compressor, and proper lubricating and sealing functions can be maintained for the compressing elements.